Export Revenue Share
38%
flat
Export revenue remained at 38% of total revenue in Q4 FY26.
VIMTALABS
Diversified
2026-04-??
Vimta Labs Ltd — Q4 FY26
Vimta Labs delivered a strong Q4 FY26 with revenue of ₹112 crore (+16.6% YoY) and EBITDA of ₹42.1 crore (+21.5% YoY), driven by robust performance in pharma and food testing.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Vimta Labs delivered a strong Q4 FY26 with revenue of ₹112 crore (+16.6% YoY) and EBITDA of ₹42.1 crore (+21.5% YoY), driven by robust performance in pharma and food testing. EBITDA margin expanded to 37.6% (+150 bps YoY), among the best in the industry. The company entered biologics CRD services, with infrastructure ready and client discussions underway. Management targets maintaining 20-25% revenue CAGR and sustaining margins around 35%, though near-term headwinds from geopolitical tensions and input cost inflation pose risks. The balance sheet remains net debt-free with ₹65 crore cash. Key risk: any escalation in global trade disruptions could impact client spending and delay growth.
Key Numbers
Full Year Revenue
₹463 million
+19.5% YoY
FY26 total income was ₹463 million, up 19.5% from ₹348.2 million in FY25.
Full Year EBITDA Margin
35.8%
-30bps YoY
FY26 EBITDA margin was 35.8%, slightly down from 36.1% in FY25.
Cash and Equivalents
₹650 million
flat
Company maintains a net debt-free balance sheet with cash and equivalents of ₹650 million.
Management Guidance
Target 20-25% revenue CAGR
Management targets maintaining historical CAGR of 20-25% annually, aiming for ₹500 crore revenue run-rate.
Management guidance growthEBITDA margin to remain around 35%
Management expects EBITDA margin to sustain in the 35% range, with possible 1-2% correction due to input cost and manpower inflation.
Management guidance marginsBiologics CRD to start in FY27
Infrastructure and team are ready; initial projects expected from domestic clients, with international traction building.
Management guidance expansionKey Risks
Geopolitical disruptions and input cost inflation
The Iran-US war has increased consumable costs and lead times, impacting margins and operations.
medium · management_commentaryElectronics testing underperformance
Electronics and electrical testing segment faced leadership challenges and did not meet expectations; recovery is uncertain.
medium · management_commentaryBiologics CRD margin uncertainty
Early biologics projects may have lower margins due to high input costs and domestic client mix; global ramp-up is unproven.
medium · analyst_questionNotable Quotes
Our focus remains on sustaining margins in a stable and competitive range over the medium term.
The purpose of undertaking this is to be closer to our customers because we have a sizable population there and also to give them greater confidence.
We have good inquiries and we will be closing them soon. We have a good traction from Europe, from India, a couple of them from US as well.
Frequently Asked Questions
What was Vimta Labs's revenue in Q4 FY26?
Vimta Labs reported revenue of ₹112 Cr in Q4 FY26, representing a +16.6% change compared to the same quarter last year.
What guidance did Vimta Labs management give for FY27?
Target 20-25% revenue CAGR: Management targets maintaining historical CAGR of 20-25% annually, aiming for ₹500 crore revenue run-rate. EBITDA margin to remain around 35%: Management expects EBITDA margin to sustain in the 35% range, with possible 1-2% correction due to input cost and manpower inflation. Biologics CRD to start in FY27: Infrastructure and team are ready; initial projects expected from domestic clients, with international traction building.
What are the key risks for Vimta Labs in FY27?
Key risks include Geopolitical disruptions and input cost inflation — The Iran-US war has increased consumable costs and lead times, impacting margins and operations.; Electronics testing underperformance — Electronics and electrical testing segment faced leadership challenges and did not meet expectations; recovery is uncertain.; Biologics CRD margin uncertainty — Early biologics projects may have lower margins due to high input costs and domestic client mix; global ramp-up is unproven..
Did Vimta Labs meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Vimta Labs Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.